Peptide Initiative

Peptides · Peptide comparison

Lixisenatide vs Semaglutide

Short-acting prandial GLP-1 receptor agonist for postprandial glucose control

The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangeLixisenatide20–20 mcgSemaglutide0.5–1 mg
FrequencyLixisenatideOnce dailySemaglutideOnce weekly
AdministrationLixisenatidesubcutaneous injectionSemaglutideSubcutaneous injection
Cycle lengthLixisenatideOngoing/indefiniteSemaglutideOngoing/indefinite
Onset speedLixisenatideModerate (1-2 weeks)SemaglutideModerate (1-2 weeks)
Evidence levelLixisenatideStrong human trials (Phase 3 or FDA approved)SemaglutideStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Blood Sugar Control

Lixisenatide9%
SemaglutideNo recorded rating

Cardiovascular Safety

Lixisenatide7%
SemaglutideNo recorded rating

Weight Management

Lixisenatide6%
SemaglutideNo recorded rating

Weight Loss

LixisenatideNo recorded rating
Semaglutide98%

Appetite Control

LixisenatideNo recorded rating
Semaglutide95%

Heart Protection

LixisenatideNo recorded rating
Semaglutide92%

Technical data

Compound specifications

Lixisenatide

Molecular formula
C215H347N61O65S
Molecular weight
4,858 Da
Half-life
2.8-3 hours
Bioavailability
55% subcutaneous bioavailability
CAS number
320367-13-3

Semaglutide

Molecular formula
C187H291N45O59
Molecular weight
4113.58 g/mol
Half-life
Approximately 7 days (168 hours)
Bioavailability
89% (subcutaneous); 0.4-1% (oral, with absorption enhancer)
CAS number
910463-68-2

Protocols

Dosing compared

Lixisenatide

Subcutaneous

  • Weeks 1-210 mcgOnce daily · Days 1-14FDA-label (Adlyxin) starting dose given once daily for 14 days using the green starter pen; injected in abdomen, thigh, or upper arm within one hour before the first meal of the day [6].
  • Day 1520 mcgOnce daily · From day 15 onwardFDA-label maintenance dose, started on day 15 using the burgundy pen for ongoing type 2 diabetes glycemic control [6].

Semaglutide

Subcutaneous

  • 4 weeks0.25 mgOnce weekly · 4 weeksThis is the starter dose to help your body adjust. It does not lower blood sugar much on its own, so it is only used for the first 4 weeks before stepping up [5].
  • At least 4 weeks at each step0.5-1 mgOnce weekly · At least 4 weeks at each stepAfter the starter month, the dose goes up to 0.5 mg, and can rise to 1 mg if more blood sugar control is needed. Wait at least 4 weeks before each increase [5].
  • Ongoing/maintenance2-2.4 mgOnce weekly · Ongoing/maintenanceThe highest weekly doses. 2 mg is the maximum for diabetes (Ozempic) [5]; up to 2.4 mg is used for weight management (Wegovy) after a slower titration.

Oral

  • 30 days3 mgOnce daily · 30 daysThe pill form (Rybelsus) starts at 3 mg each morning for 30 days. Like the starter shot, this dose is for getting started and does not control blood sugar by itself. Take on an empty stomach with a small sip of water, 30 minutes before food or other pills [6].
  • 30+ days7 mgOnce daily · 30+ daysAfter the first 30 days, the dose increases to 7 mg once daily. This is the first dose that actively lowers blood sugar [6].
  • Ongoing/maintenance14 mgOnce daily · Ongoing/maintenanceThe highest pill dose, used if more blood sugar control is needed after at least 30 days at 7 mg [6].

Applications

Best suited for

Lixisenatide

Managing postprandial hyperglycemia in type 2 diabetes
Lixisenatide is particularly well-suited for individuals focused on managing postprandial hyperglycemia in type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving glycemic control as add-on to oral antidiabetics
Lixisenatide is particularly well-suited for individuals focused on improving glycemic control as add-on to oral antidiabetics. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting weight management in T2DM patients
Lixisenatide is particularly well-suited for individuals focused on supporting weight management in t2dm patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Combination therapy with basal insulin glargine
Lixisenatide is particularly well-suited for individuals focused on combination therapy with basal insulin glargine. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Semaglutide

People with Obesity Seeking Significant Weight Loss
If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. [7] Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds [1].
Those Who've Struggled with Diet and Exercise Alone
Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less [3][7][13].
People with Type 2 Diabetes Needing Better Control
Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. [3][5] It can often allow people to reduce or eliminate other diabetes medications [21].
Individuals at High Cardiovascular Risk
The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes [2].

Safety profile

Side effects

Lixisenatide

Common

  • Nausea
  • Vomiting
  • Diarrhea
  • Headache

Uncommon

  • Injection Site Reactions

Serious

  • Acute Pancreatitis

Semaglutide

Common

  • Nausea
  • Constipation or Diarrhea
  • Decreased Appetite
  • Vomiting

Uncommon

  • Gallbladder Problems
  • Hair Loss (Telogen Effluvium)

Serious

  • Pancreatitis
  • Thyroid Tumors (Theoretical Risk)

Research status

Safety & evidence

Lixisenatide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Lixisenatide (ADLYXIN in the US, Lyxumia in the EU) is an FDA-approved GLP-1 receptor agonist for type 2 diabetes; its safety record comes from the GetGoal phase 3 trials and the ELIXA cardiovascular outcomes trial. [1][6] In the pooled placebo-controlled trials, gastrointestinal reactions affected 39.7% of patients against 18.4% on placebo, mostly in the first 3 weeks; nausea affected 25% and vomiting 10%. [6] Labelled warnings cover anaphylaxis and serious hypersensitivity, pancreatitis (21 cases on lixisenatide against 14 on comparators), hypoglycemia when combined with a sulfonylurea or basal insulin, acute kidney injury after severe GI fluid loss, antibody formation and gallbladder disease. [6] Unlike the long-acting GLP-1 agonists, its label carries no boxed thyroid C-cell tumor warning. [6]

Contraindications

  • Known hypersensitivity to lixisenatide or excipients [6]

Semaglutide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. [1][2][8][9][10] The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. [1][7] The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss [2].

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC) [7]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [7]
  • History of serious allergic reaction to semaglutide [7]

Decision guide

Which is right for you?

Lixisenatide

Choose Lixisenatide if…

  • Managing postprandial hyperglycemia in type 2 diabetes
  • Improving glycemic control as add-on to oral antidiabetics
  • Supporting weight management in T2DM patients
  • Combination therapy with basal insulin glargine

Semaglutide

Choose Semaglutide if…

  • Significant weight loss
  • Long-term weight management
  • Cardiovascular risk reduction
  • Blood sugar control